Non-classic <i>EGFR</i> mutations in a cohort of Dutch <i>EGFR</i>-mutated NSCLC patients and outcomes following EGFR-TKI treatment



Kuiper, JL, Hashemi, SMS, Thunnissen, E, Snijders, PJF, Grunberg, K, Bloemena, E, Sie, D, Postmus, PE ORCID: 0000-0002-7774-2868, Heideman, DAM and Smit, EF
(2016) Non-classic <i>EGFR</i> mutations in a cohort of Dutch <i>EGFR</i>-mutated NSCLC patients and outcomes following EGFR-TKI treatment. BRITISH JOURNAL OF CANCER, 115 (12). pp. 1504-1512.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4>Data on non-small-cell lung cancer (NSCLC) patients with non-classic epidermal growth factor receptor (EGFR) mutations are scarce, especially in non-Asian populations. The purpose of this study was to evaluate prevalence, clinical characteristics and outcome on EGFR-TKI treatment according to type of EGFR mutation in a Dutch cohort of NSCLC patients.<h4>Methods</h4>We retrospectively evaluated a cohort of 240 EGFR-mutated NSCLC patients. Data on demographics, clinical and tumour-related features, EGFR-TKI treatment and clinical outcome were collected and compared between patients with classic EGFR mutations, EGFR exon 20 insertions and other uncommon EGFR mutations.<h4>Results</h4>Classic EGFR mutations were detected in 186 patients (77.5%) and non-classic EGFR mutations in 54 patients (22.5%); 23 patients with an exon 20 insertion (9.6%) and 31 patients with an uncommon EGFR mutation (12.9%). Median progression-free survival (PFS) and overall survival (OS) on EGFR-TKI treatment were 2.9 and 9.7 months, respectively, for patients with an EGFR exon 20 insertion, and 6.4 and 20.2 months, respectively, for patients with an uncommon EGFR mutation. Patients with a double uncommon EGFR mutation that included G719X/L861Q/S768I had longer PFS and OS on EGFR-TKI treatment compared with patients with a single G719X/L861Q/S768I EGFR mutation (both P=0.02).<h4>Conclusions</h4>In our Dutch cohort, prevalence and genotype distribution of non-classic EGFR mutations were in accordance with previously reported data. The PFS and OS on EGFR-TKI treatment in patients with an uncommon EGFR mutation were shorter compared with patients with classic EGFR mutations, but varied among different uncommon EGFR mutations.

Item Type: Article
Uncontrolled Keywords: NSCLC, classic EGFR mutation, non-classic EGFR mutation, EGFR-TKI, TKI, EGFR
Depositing User: Symplectic Admin
Date Deposited: 30 Jan 2019 11:28
Last Modified: 12 Oct 2023 07:01
DOI: 10.1038/bjc.2016.372
Open Access URL: https://doi.org/10.1038/bjc.2016.372
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3032003